Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/m3-inc" target="_blank" data-smartkarma-citation="entities:13316:1" rel="noopener">M3 Inc (2413 JP)</a>  provides various medical-related services to physicians and healthcare professionals in Japan and overseas. The company operates m3.com, its key platform alongside several other websites and platforms aimed at providing different services such as information provision, marketing services, medical health records and career solutions for physicians and medical practitioners.The company share price has more than doubled to JPY6,380 per share (from JPY2,921 on 26th March 2020) since we last wrote on the company. In this insight, we examine the key catalysts behind the company’s share price rally and the valuation.

M3 Inc (2413 JP)  provides various medical-related services to physicians and healthcare professionals in Japan and overseas. The company operates m3.com, its key platform alongside several other websites and platforms aimed at providing different services such as information provision, marketing services, medical health records and career solutions for physicians and medical practitioners.The company share price has more than doubled to JPY6,380 per share (from JPY2,921 on 26th March 2020) since we last wrote on the company. In this insight, we examine the key catalysts behind the company’s share price rally and the valuation.

M3 Inc: Intelligent Adaption to Covid-19 Should Sustain Medtech Earnings Growth Even Post-Pandemic

Equity Capital Markets

GoodRx Holdings Inc / Equity Capital Markets

GoodRx (GDRX) offers a prescription aggregation platform in the US enabling healthcare professionals to provide prices from the platform directly to their patients at the point of prescribing. In addition, the company also offers telehealth services since 2019 through its own platform HeyDoctor and GoodRx telehealth marketplace.The company has filed for an IPO in the US and intends to raise around US$900m. In addition, GoodRx will also raise US$100m from a private placement from Silver Lake concurrent to its IPO.A majority of the recent IPOs in the US commanded lofty valuations despite them making massive losses while some of them did not even have a proper path to profitability. However, GoodRx has strong financials with a growing top line and track record of profits, and the company dominates a growing market.We discuss the details below.

GoodRx (GDRX) offers a prescription aggregation platform in the US enabling healthcare professionals to provide prices from the platform directly to their patients at the point of prescribing. In addition, the company also offers telehealth services since 2019 through its own platform HeyDoctor and GoodRx telehealth marketplace.The company has filed for an IPO in the US and intends to raise around US$900m. In addition, GoodRx will also raise US$100m from a private placement from Silver Lake concurrent to its IPO.A majority of the recent IPOs in the US commanded lofty valuations despite them making massive losses while some of them did not even have a proper path to profitability. However, GoodRx has strong financials with a growing top line and track record of profits, and the company dominates a growing market.We discuss the details below.

GoodRx IPO: A Healthy Prescription for Strong Topline Growth and Profits

United States

GoodRx Holdings, Inc. operates a digital healthcare platform. The Company develops tele-medicine platform and a free-to-use website. GoodRx Holdings serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GoodRx Holdings Inc (GDRX US)

M3 Inc: Intelligent Adaption to Covid-19 Should Sustain Medtech Earnings Growth Even Post-Pandemic

M3 Inc (2413 JP) provides various medical-related services to physicians and healthcare professionals in Japan and overseas. The company operates...

Shifara Samsudeen, FCMA, CGMA

GoodRx IPO: A Healthy Prescription for Strong Topline Growth and Profits

GoodRx (GDRX) offers a prescription aggregation platform in the US enabling healthcare professionals to provide prices from the platform directly...

Shifara Samsudeen, FCMA, CGMA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)